Genetic Factors Affect Antiseizure Medication Reactions in Peru

Source: Pharmaceuticals (Basel, Switzerland)

Summary

A study was conducted to explore how certain genetic variations affect the way Peruvian patients with epilepsy respond to antiseizure medications. Researchers focused on two specific genes, CYP2C9 and CYP2C19, which are important for drug metabolism. The study included 89 patients from a hospital in Peru, with an average age of around 24 years, and aimed to see if these genetic differences were linked to adverse reactions from the medications.

The key findings showed that patients with certain genetic variations in the CYP2C9 and CYP2C19 genes had a higher risk of experiencing negative side effects from their medications. Specifically, those with intermediate or poor metabolism of these genes were about four times more likely to have adverse drug reactions compared to those with normal metabolism. Additionally, patients taking multiple medications (polytherapy) were also at a greater risk of experiencing these side effects.

This research is important because it highlights how genetic testing can help doctors better understand which patients might be at risk for medication side effects, potentially leading to safer treatment plans. However, the study is limited to a specific group of patients in Peru, so the findings may not apply to all populations. More research is needed to confirm these results and to explore how genetic factors can influence medication responses in different regions.

Original source